Validation of Horizon Technology Disk Extraction Technology for US EPA Wastewater Method 625.1
Special Issues
The US EPA monitors a variety of chemicals in water that may cause harm to humans or wildlife to minimize exposure.
Zoe Grosser*, Alicia Cannon*, Michael Ebitson*, Melissa Lever*, Nic Rasnake†, Jessica Bowker†, Allen Fuller†, and Chris Johnson†, *Horizon Technology, and †ESC Lab Sciences
The US EPA monitors a variety of chemicals in water that may cause harm to humans or wildlife to minimize exposure. Method 625 was developed by the Office of Science and Technology in the Clean Water program to allow the monitoring of a large suite of semivolatile chemicals in wastewater for compliance with the National Pollution Discharge Elimination System (NPDES). NPDES is a system of permitting that defines the characteristics of water that is released into a waterway, defined by industrial category. The permitting levels are set depending on the waterway’s use. If the waterway is used for recreation or is an important wildlife habitat, the limit may be set lower.
The original method was developed in the early 1980s and has been updated several times since then to allow the use of more modern technology. The latest update has taken place over the last few years and was proposed in a Method Update Rule (MUR) in 2015 (1). The latest version of the method includes a larger suite of analytes (up to 364) and an extensive set of labeled surrogates to better monitor the method performance throughout the sample preparation and analysis step.
This application note will present the data collected as part of the demonstration of disk solid phase extraction validation for US EPA Method 625.1. Nine different wastewater matrices were evaluated and tested against the criteria listed in Table 6 of Method 625.1. Sample preparation was performed using the Atlantic® One-pass system, where the water sample is passed through a solid phase extraction (SPE) disk and carbon cartridge once, rather than twice with a pH change between loadings. Automation of the process was achieved using the SPE-DEX® 4790 system (superseded by SPE-DEX 5000). Table I shows method detection limits obtained in this work for selected compounds, compared with detection limits listed in the method. In most cases, the method detection limits are significantly better than those obtained using liquid-liquid extraction and older technology. Results for complex samples were also excellent and are detailed in the full application note (2).
References
- Method 625.1, December 14 revision, can be found in the MUR (February 19, 2015), or it can be downloaded here: https://nepis.epa.gov/Exe/ZyPDF.cgi/P100LVHC.PDF?Dockey=P100LVHC.PDF
- Application Note 117, “Validation of Horizon Technology Disk Extraction Technology for US EPA Wastewater Method 625.1,” available from www.horizontechinc.com.
Horizon Technology, Inc.
16 Northwestern Drive, Salem, NJ 03079
tel. (603) 893-3663
Website: www.horizontechinc.com
Using LC-MS/MS Analysis for PFAS Detection in Biological Samples and Serum
November 1st 2024Per- and polyfluoroalkyl substances (PFAS) are exceptionally versatile chemicals and have seemingly endless applications. Due to their persistent nature; prevalence in blood, food and environment; and emerging toxicity, there is a significant concern for their presence in the human body. Analysis is especially complicated due to background contamination in laboratory supplies and system. This paper will discuss sample preparation and LC-MS/MS analysis of an expanded panel of PFAS compounds in serum.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.
Identifying and Rectifying the Misuse of Retention Indices in Gas Chromatography
October 31st 2024LCGC International spoke to Phil Marriott and Humberto Bizzo about a recent paper they published identifying the incorrect use of retention indices in gas chromatography and how this problem can be rectified in practice.
